Not available
Quote | Bioblast Pharma Ltd. (NASDAQ:ORPN)
Last: | $ |
---|---|
Change Percent: | 6.68% |
Open: | $10.82 |
Close: | $11.50 |
High: | $11.50 |
Low: | $10.3163 |
Volume: | 19,768 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Bioblast Pharma Ltd. (NASDAQ:ORPN)
It has only been a few months since my first Seelos article ( SEEL ), but the company has been negotiating two deals to expand its pipeline and areas of study. The first deal was made in February with Bioblast Pharma ( ORPN ) concerning their mutant protein stabilization solution called Treh...
Tel Aviv, Israel, March 06, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced the effectiveness of an eight to one reverse split of its share capital. As previously reported, the reverse split was approv...
Message Board Posts | Bioblast Pharma Ltd. (NASDAQ:ORPN)
Subject | By | Source | When |
---|---|---|---|
I see ok, they should send a PR | MOCKBA | investorshub | 04/01/2019 12:29:13 PM |
I mean that ENLV is now Nasdaq compliant, | dinogreeves | investorshub | 04/01/2019 11:54:54 AM |
What you mean by that? | MOCKBA | investorshub | 04/01/2019 11:51:39 AM |
ENLV Nasdaq compliant now, should get a press | dinogreeves | investorshub | 04/01/2019 1:57:01 AM |
checkout website you'll be impressed | dinogreeves | investorshub | 03/30/2019 2:13:34 PM |
News, Short Squeeze, Breakout and More Instantly...
Bioblast Pharma Ltd. Company Name:
ORPN Stock Symbol:
NASDAQ Market:
Tel Aviv, Israel, March 06, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced the effectiveness of an eight to one reverse split of its share capital. As previously reported, the reverse split was approv...
CORAL GABLES, FL / ACCESSWIRE / February 19, 2019 / The success of healthcare stock market is based on whether or not companies in the healthcare industry have the ability to meet the growing demands of consumers. It's no longer a question of simply creating treatment options and offering ...
Diversifies Seelos’ pipeline in rare diseases Collaborates with Team Sanfilippo Foundation in development of Trehalose in Sanfilippo syndrome NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announc...